Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
CPRIT Funding Awards
for multi-investigator research
in support for core facilities
for new faculty recruitment
Learn more about MD Anderson’s CPRIT funding
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Our laboratories cover the full breadth of cancer research. They’re led by some of the leading scientists and physicians in the world.
Scientists from different disciplines come together to focus on a common area in our research institutes.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.Learn more about the Moon Shots Program
Nobel Prize Winner
Metastatic lung cancer
Off-the-shelf adoptive T-cell therapy
MD Anderson researchers led a Phase II trial validating adoptive T-cell therapy as an effective treatment option for progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection sometimes observed in patients with cancer. The trial used donor T cells targeting a virus similar to the one that causes PML.
We're designing colorectal cancer vaccines specific for each patient